Table 3.

Sensitivity Analysis of the RCTs Meta-Analyses (see Figure 2) and NRSIs (see Figure 3).

Moderator	N studies	HR	95% CI		Heterogeneity I2 (%)	z-score	P-value
RCTs
Including15 (active comparator)	11	0.94	0.71	1.25	64	0.41	.68
Active control instead of inactive for16	10	0.83	0.71	0.98	0	2.21	.03
Including15 and active control for16	11	0.96	0.73	1.28	66	0.26	.79
uME compared to no therapy instead of chemo for17	10	0.8	0.68	0.94	0	0.267	.008
NRSIs
Including14 (prospective NRSIs, active comparator)	8	0.68	0.45	1.03	88	1.8	.07